Nkarta, Inc.
Nkarta is a biotechnology company dedicated to harnessing the power of natural killer (NK) cells for the treatment of autoimmune diseases and cancer. The company's mission is to discover, develop, and deliver off-the-shelf NK cell therapies that profoundly impact patients' response, quality of life, and overall survival. Founded in 2015, Nkarta combines proprietary NK cell expansion technology with cell engineering to generate potent, durable, and accessible cell therapies. The company is committed to innovation, diversity, and making advanced treatments broadly available.
Industries
Nr. of Employees
medium (51-250)
Nkarta, Inc.
1150 Veterans Blvd, South San Francisco, CA 94080
Products
Investigational CAR NK cell therapy targeting CD19
An allogeneic, donor-derived CAR NK cell candidate designed to target CD19-expressing B cells for the treatment of B cell-mediated autoimmune diseases; intended for off-the-shelf outpatient administration.
Investigational CAR NK cell therapy targeting CD19
An allogeneic, donor-derived CAR NK cell candidate designed to target CD19-expressing B cells for the treatment of B cell-mediated autoimmune diseases; intended for off-the-shelf outpatient administration.
Services
Internal development and execution of GMP manufacturing processes for allogeneic cell therapy candidates and transfer of processes to GMP operations.
Development, qualification and transfer of cell-based and molecular assays to support process development, release testing and regulatory filings.
Design and execution of in vivo efficacy and pharmacology studies using oncology and immunology models to support lead selection and IND-enabling data generation.
In-house computational analysis, pipeline development and integration of public and proprietary -omics datasets to support target discovery and biomarker strategies.
Internal development and execution of GMP manufacturing processes for allogeneic cell therapy candidates and transfer of processes to GMP operations.
Development, qualification and transfer of cell-based and molecular assays to support process development, release testing and regulatory filings.
Design and execution of in vivo efficacy and pharmacology studies using oncology and immunology models to support lead selection and IND-enabling data generation.
In-house computational analysis, pipeline development and integration of public and proprietary -omics datasets to support target discovery and biomarker strategies.
Expertise Areas
- Cell therapy process development
- Allogeneic NK cell engineering
- Analytical assay development for cell therapies
- Preclinical in vivo pharmacology and model development
Key Technologies
- Flow cytometry (multicolor)
- qPCR
- ELISA / MSD immunoassays
- Cell-based cytotoxicity and proliferation assays
News & Updates
Nkarta Presents Preclinical Data at AACR
Nkarta announced preclinical data demonstrating the potency and persistence of engineered NK cells, highlighting their potential for cancer therapy.
Nkarta Appoints New Leadership and Board Members
Nkarta announced the appointment of Paul Hastings as CEO and the addition of new independent directors to its board.
Nkarta Receives Funding and Strategic Support
The company secured investment from leading biotech investors to advance its pipeline and manufacturing capabilities.
Nkarta's Innovative NK Cell Platform Shows Promise in Cancer Treatment
A review of Nkarta's proprietary NK cell expansion and engineering technology and its potential to revolutionize cell therapy.
Leadership Insights: Nkarta's Vision for Autoimmune Disease Therapies
Interviews with Nkarta's CEO Paul Hastings on the company's mission and future directions.
Nkarta's Clinical Pipeline and Next-Generation Cell Therapies
An overview of Nkarta's pipeline, including NKX019 and other engineered NK cell candidates.
Nkarta Presents Preclinical Data at AACR
Nkarta announced preclinical data demonstrating the potency and persistence of engineered NK cells, highlighting their potential for cancer therapy.
Nkarta Appoints New Leadership and Board Members
Nkarta announced the appointment of Paul Hastings as CEO and the addition of new independent directors to its board.
Nkarta Receives Funding and Strategic Support
The company secured investment from leading biotech investors to advance its pipeline and manufacturing capabilities.
Nkarta's Innovative NK Cell Platform Shows Promise in Cancer Treatment
A review of Nkarta's proprietary NK cell expansion and engineering technology and its potential to revolutionize cell therapy.
Leadership Insights: Nkarta's Vision for Autoimmune Disease Therapies
Interviews with Nkarta's CEO Paul Hastings on the company's mission and future directions.
Nkarta's Clinical Pipeline and Next-Generation Cell Therapies
An overview of Nkarta's pipeline, including NKX019 and other engineered NK cell candidates.